Medicament for preventing in-stent restenosis after coronary stent implantation and preparation method

A coronary artery and restenosis technology, applied in the field of medicine and its preparation, can solve the problems of poor curative effect, high cost, and large side effects, and achieve the effects of reducing concentration, improving clinical symptoms, and having no toxic and side effects

Active Publication Date: 2013-01-16
贵州中医药大学
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, technologies such as radioactive stents and drug-eluting stents are usually used to alleviate ISR, but there are disadvantages such as large side effects, high cost, and poor curative effect. There is no Chinese medicine compound capsule with obvious curative effect in preventing and treating ISR.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1. Take the crude drug Salvia miltiorrhiza, crush it into a coarse powder, add ethanol to heat and reflux for extraction three times, filter, combine the filtrate, recover the ethanol under reduced pressure and concentrate it into a thick paste with a relative density of 1.30-1.35, wash with hot water until the lotion is colorless, 80°C Dry, pulverize into fine powder to obtain tanshinone, weigh 1000g for later use; take 25g of borneol and grind into fine powder for later use: combine the above-mentioned raw material medicine with 250g of raw material medicine hirudin and 7.5g of muscone, mix well, add auxiliary materials, and make capsules 1000 capsules, 1g per capsule. This product (that is, Danzhi ice musk deer compound traditional Chinese medicine monomer capsule) is taken orally, 1-3 capsules each time, 3 times a day.

Embodiment 2

[0043] Example 2. Take the crude drug Salvia miltiorrhiza, crush it into a coarse powder, add ethanol to heat and reflux for extraction three times, filter, combine the filtrate, recover the ethanol under reduced pressure and concentrate it into a thick paste with a relative density of 1.30-1.35, wash with hot water until the lotion is colorless, 80°C Dry, pulverize into fine powder to obtain tanshinone, weigh 1200g for later use; take 30g of borneol and grind into fine powder for later use: combine the above-mentioned raw material medicine with raw material medicine hirudin 300g and muscone 9g, mix evenly, add auxiliary materials, and make granules 1000g bags, 1g per bag. This product is taken orally, 1-3 bags each time, 3 times a day.

Embodiment 3

[0044] Example 3. Take the crude drug Salvia miltiorrhiza, crush it into a coarse powder, add ethanol to heat and reflux for extraction three times, filter, combine the filtrate, recover the ethanol under reduced pressure and concentrate it into a thick paste with a relative density of 1.30-1.35, wash with hot water until the lotion is colorless, 80°C Dry, pulverize into fine powder to obtain tanshinone, weigh 800g for subsequent use; take 20g of borneol and grind into fine powder for subsequent use: combine the above-mentioned crude drug with 200g of crude drug hirudin and 6g of muscone, mix well, add auxiliary materials, and make a tablet 1000g slices, 1g per slice. This product is taken orally, 1-3 tablets each time, 3 times a day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicament for preventing in-stent restenosis after coronary stent implantation and a preparation method. The medicament is prepared into 1000 parts from, by weight, 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of camphol and borneol and 6-9 parts of musk ketone. The medicament has the advantages of effective treatment, no toxic and side effects and capabilities of decreasing occurrence rate of in-stent restenosis after coronary stent implantation, obviously improving clinical symptoms of patients and reducing long-term risks of thrombosis of the patients, and is obvious in clinical effect. The medicament provides a new choice for preventing ISR (in-stent restenosis) after coronary stent implantation.

Description

[0001] technical field [0002] The invention relates to a medicine and a preparation method thereof, in particular to a medicine for preventing restenosis after coronary artery stent implantation and a preparation method thereof, belonging to the technical field of medicine. Background technique [0003] With the aggravation of the aging society, the incidence of coronary heart disease in my country has increased significantly; coronary artery stent implantation is an important means of treatment of coronary heart disease, it effectively avoids the elastic recoil of blood vessels and vascular reconstruction after balloon dilatation, and at the same time To a large extent, the shortcomings of coronary artery bypass surgery such as large wound, difficult recovery, and high surgical risk are avoided. However, restenosis after coronary stent implantation (abbreviation: ISR) has also become a problem that cannot be ignored, which limits the use and promotion of this technology. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/55A61P9/10A61K31/045A61K31/122A61K31/58
Inventor 许滔
Owner 贵州中医药大学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap